Skip to main content

Nxera Pharma

corporate_fare Company Profile

Nxera Pharma

SOLTF·OTC·Life Sciences

Nxera Pharma is a biopharmaceutical company engaged in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. It offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. Its pipeline includes NBI-1117568, a muscarinic M4 agonist in a phase 3 trial for schizophrenia, dementia and other neuropsychiatric disorders; ORX750, an OX2 agonist for narcolepsy, idiopathic hypersomnia, and other sleep-wake disorders; NBI-1117570, a dual muscarinic M1/M4 agonist; and HTL0039732, an EP4 antagonist immunotherapy drug. Phase 1 products include PF-07054894, a CCR6 antagonist, and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, an MC4 antagonist for anorexia; NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, an mGlu5 NAM for substance use disorders; and NXE0048149, a GPR52 agonist for schizophrenia. Preclinical products comprise KY1051, a CXCR4 mAb for immuno-oncology, and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. The company also develops other discovery-stage drugs. It has strategic collaborations with Tempero Bio, Pharmenable Therapeutics, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Lilly, AbbVie, Genentech, Pfizer, Neurocrine Biosciences, Antiverse, and Novartis International AG. The company was formerly known as Sosei Group Corporation, was incorporated in 1990, and is headquartered in Minato, Japan.

Nxera Pharma (OTC:SOLTF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for SOLTF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10.

Recent high-impact activity:

  • AbbVie Pays $100M Upfront in $1.5B Bowel Disease Licensing Deal

Short Interest & Short Volume

FINRA reported short interest of 1,900,311 shares in SOLTF as of the October 30, 2026 settlement, a 11.6% increase from the prior period. On November 20, 2026, 67.6% of SOLTF volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,900,311 shares as of October 30, 2026
Change vs prior period▲ 11.6%
Daily short volume (FINRA facilities)67.6% of 1,700 shares on November 20, 2026

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$9.89 -5.76% today
52-week range · as of 2026-11-04 $4.9 – $22.78
Market cap
$916.43M
Volume
1.7K (0.5× avg)
3-mo avg 3.6K
Live data · 2026-11-22 12:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SOLTF - Latest Insights

SOLTF
Nov 04, 2026, 1:22 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $8.50
Real-time Price: $9.90 info
Change: +$1.39 (+16%) info
Market Cap: $916.427M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets